Versartis, Inc.
VSAR
NASDAQ1.19
USD
-0.03
- -
CIK
0001513818
Return %
Stock
S&P500
1Y
- -
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- IPO Date
- Mar 21, 2014
- CIK
- 0001513818
- Similar Companies
- Business
- Versartis, Inc. (VSAR) develops and commercializes recombinant fusion protein therapeutics focused on treating endocrine and metabolic disorders, with its lead product candidate somavaratan (formerly VRS-317) designed as a long-acting growth hormone for pediatric and adult growth hormone deficiency. The company offers proprietary half-life extension technology platforms, including the proprietary XPOLY platform for creating extended half-life peptides and proteins; and preclinical programs targeting obesity, diabetes, and hypoparathyroidism. Versartis operates primarily in the United States and Europe, targeting patients with rare endocrine conditions through partnerships with endocrinologists and pediatric specialists, and maintains its headquarters in Menlo Park, California, following its founding in 2007 [ from prior searches, noting biotech context]. In late 2018, Versartis entered into a definitive merger agreement with Pinnaclecare Oncology, which led to its delisting from Nasdaq and a shift away from independent public operations as of 2019, with no significant new product launches, funding rounds, acquisitions, or strategic expansions reported in the last 1-2 years. The company previously pursued clinical trials for somavaratan across multiple Phase 2 and Phase 3 studies in pediatric growth hormone deficiency before the merger, but current activities remain limited post-delisting.